Full-Year EBITDA Margin Guidance: Between 26% and 30%. Bavarian Nordic AS (BVNKF) reported a strong start to the year with a 62% growth in revenue, reaching almost 1.4 billion krona. The company ...

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names ...

The CDC and FDA advise against Ixchiq chikungunya vaccine for American travellers aged 60 and above. This is due to reported heart and brain-related i ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Access Bavarian Nordic ADR stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

Chikungunya vaccine is linked to severe complications in older adults Live virus vaccine caused hospitalizations and two ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...